Claims for Patent: 7,148,220

Summary for Patent: 7,148,220

Title:	C-6 modified indazolylpyrrolotriazines
Abstract:	The present invention provides compounds of formula I ##STR00001## and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Inventor(s):	Vite; Gregory D. (Titusville, NJ), Gavai; Ashvinikumar V. (Princeton Junction, NJ), Fink; Brian E. (Princeton Junction, NJ), Mastalerz; Harold (Guilford, CT), Kadow; John F. (Wallingford, CT)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	11/143,279
Patent Claims:	1. A method for treating breast, ovarian, gastric and bladder cancer, comprising administering to a warm-blooded species in need thereof, a therapeutically effective amount of a compound of the formula ##STR00205## wherein R is selected from the group consisting of aryl, substituted aryl, heterocyclo, and substituted heterocyclo; R.sup.1 is selected from the group consisting of alkyl and substituted alkyl; R.sup.2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl, heterocyclo, and substituted heterocyclo; or, R.sup.2 may be absent; X is selected from the group consisting of a bond, O, S, C(R.sup.3).sub.2, C(R.sup.3).sub.3, NR.sup.3; and N(R.sup.3).sub.2; R.sup.3 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, heterocyclo, and substituted heterocyclo, or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 2. The method of claim 1 further comprising administering to a warm-blooded species in need thereof, a therapeutically effective amount of at least one other anti-cancer or cytotoxic agent. 3. The method of claim 2 wherein said anti-cancer or cytotoxic agent is selected from the group consisting of tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, metalloproteinase inhibitors, inhibitors of insulin growth receptor, growth factor antibodies, growth factor receptor antibodies, bevacizumab, cetuximab, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, methotrexate, 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa, vincristine, vinorelbine, vinblastine, vinflunine paclitaxel, docetaxel, epothilone analogs, discodermolide analogs, eleutherobin analogs, etoposide, teniposide, amsacrine, topotecan, irinotecan, flavopyridols, and bortezomib.

Details for Patent 7,148,220

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2022-12-13
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2022-12-13
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2022-12-13